Mabwell (Shanghai) Bioscience Co., Ltd. Announces Poll Results from 2026 Second Extraordinary General Meeting: Key Takeaways for Investors
Summary of the Announcement
On June 1, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell” or the “Company”, Stock Code: 2493) held its 2026 Second Extraordinary General Meeting (EGM) at its Shanghai headquarters. The meeting was presided over by Dr. Liu Datao, Chairman and Executive Director. All directors participated, either in person or electronically. The EGM was convened and conducted in accordance with PRC laws and the Company’s Articles of Association.
Key Points for Investors
- Major Resolution Approved: Shareholders overwhelmingly approved the Company’s proposal to apply for the registration and issuance of targeted debt financing instruments. This resolution passed with 99.7470% votes in favour, a clear signal of shareholder support for the Company’s financing strategy.
-
Voting Details:
- Total issued shares: 446,730,200 (399,600,000 A Shares and 47,130,200 H Shares).
- Treasury shares: 1,192,369 A Shares (with no voting rights exercised at the EGM).
- Total shares entitled to vote: 445,537,831.
- No shares were subject to abstention or special voting arrangements under Hong Kong Listing Rules.
- Legal Compliance: The meeting and voting procedures were supervised by Merits & Tree Law Offices, the Company’s PRC legal advisers, who confirmed that all procedures complied with relevant laws and the Articles of Association. The poll results are valid.
Potential Price-Sensitive Information
- Targeted Debt Financing Instruments: The approval to apply for and issue targeted debt instruments is significant. If successfully executed, this will allow Mabwell to raise funds for its operations, R&D, or other strategic initiatives. Such financing can impact the Company’s capital structure, liquidity, and future growth plans, potentially affecting share value.
- Strong Shareholder Support: The overwhelming majority vote suggests high investor confidence in Mabwell’s management and strategic direction.
Other Noteworthy Details
- Board Composition: As of the announcement date, the Board comprises five executive directors (including Dr. Liu Datao as Chairman), one non-executive director, and four independent non-executive directors. This robust governance structure supports effective decision-making.
- Transparency in Voting Process: Tricor Investor Services Limited acted as scrutineer for the H Share polls, ensuring transparency and accuracy in vote counting.
Conclusion
The EGM’s outcome indicates Mabwell’s proactive approach to capital management and financing. Investors should closely monitor subsequent announcements regarding the actual issuance of debt instruments and their impact on the Company’s financial position.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisers before making investment decisions. The information is based on official Company disclosures as of June 1, 2026.
香港邁威生物科技股份有限公司2026年第二次臨時股東大會投票結果公告：投資者重點資訊
公告摘要
2026年6月1日，邁威（上海）生物科技股份有限公司（「邁威」或「公司」，股份代號：2493）於上海總部舉行2026年第二次臨時股東大會（EGM）。會議由董事會主席兼執行董事劉大濤博士主持，全體董事均親臨或以電子方式出席。大會依法及依公司章程規定召開及進行。
投資者重點
- 主要決議獲得通過： 股東高票通過公司申請註冊發行定向債務融資工具的提案，99.7470%的股東投贊成票，顯示對公司融資策略的明確支持。
-
投票詳情：
- 公司發行股份總數：446,730,200（其中A股399,600,000股，H股47,130,200股）。
- 公司庫存股：1,192,369股A股（該部分無表決權）。
- 有權投票股份總數：445,537,831。
- 沒有股份需依香港上市規則棄權或特別投票安排。
- 法律合規： 會議及投票程序由公司法律顧問競天樹律師事務所（Merits & Tree Law Offices）全程監督，並確認一切符合法律法規及公司章程，投票結果有效。
可能影響股價的重要資訊
- 定向債務融資工具： 此項決議獲批意味公司將可發行債務工具募集資金，支持日常運營、研發或其他戰略部署，對公司資本結構、流動性及未來發展有潛在影響，或對股價產生影響。
- 強勁的股東支持： 決議獲得壓倒性贊成，反映投資者對管理層及公司戰略高度信心。
其他須知細節
- 董事會組成： 截至公告日，董事會有五位執行董事（包括主席劉大濤博士）、一位非執行董事及四位獨立非執行董事，治理結構完善。
- 投票過程透明： H股投票由卓佳證券登記有限公司（Tricor Investor Services Limited）監票，確保公開、公正。
結論
本次EGM結果顯示邁威積極優化資本管理，投資者應持續關注公司後續有關債務工具發行進展及其對公司財務狀況的實際影響。
免責聲明
本文僅供資訊參考，並不構成任何投資建議。投資者應自行進行盡職調查並諮詢專業顧問後作出投資決策。資訊基於公司2026年6月1日公告。
